Cantor Fitzgerald Downgrades TrovaGene (TROV) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq slides to near one-month low as AI rout deepens
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent oil slips as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts TROV Hot Sheet
Price: $1.19 --0%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Join SI Premium – FREE
Cantor Fitzgerald downgraded TrovaGene (NASDAQ: TROV) from Buy to Hold with a price target of $5.00 (from $9.00).
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $4.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft (MSFT) PT Raised to $675 at UBS as 'Valuation Multiple Is Not Stretched'
- SAP AG (SAP) PT Raised to $250 at TD Cowen
- ServiceNow (NOW) PT Raised to $165 at TD Cowen
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
